

STRICTLY CONFIDENTIAL

This presentation has been prepared by Cardiex Limited, (Cardiex or the Company), solely for its use in discussions between the Company and potential investors. The information contained in this presentation is an overview and does not contain all information necessary to make investment decisions. Although reasonable care has been taken to ensure that facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation and no reliance should be placed on such information or opinions. This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the Company nor does it constitute financial advice nor take into consideration your investment objectives.

This presentation contains or may contain forward-looking statements that are based on management's belief, assumptions and expectations and on information currently available to management. All statements that are not historical, including those statements that address future operating performance and events of developments that we expect or anticipate will occur in the future, are forward-looking statements. Although management believes these forward-looking statements are fair and reasonable you should not place undue reliance on these statements.

CRAIG COOPER - CEO

Australia

Co-Founder - NRG Asia—Pacific (Australia's largest independent energy producer)

Founder – Private Energy Partners (PEP)

Partner – M-Mobile (largest independent mobile retail distribution company in Australia)

Senior Associate Lawyer – Blake Dawson Waldron – counsel to United Airlines, The Disney Corporation, DHL International (External General Legal Counsel)

"Craig has built and transformed some of the leading businesses in consumer Internet and digital media. He has a vision for big market opportunities and a passion for living life to the fullest."

Anthony Robbins | Entrepreneur, Author and Peak Performance Strategist

USA

Co-Founder - Boost Mobile USA

Managing Partner – The Action Fund

Investor - The Huffington Post (acquired by AOL), BuzzFeed (USD\$3B), Buddy Media (acquired by Salesforce), Associated Content (acquired by Yahoo), xAD (USD\$1B)

TV Host & Investor – CNBC's "Adventure Capitalists"

Head of Venture Capital and Digital Media – Saban Capital (\$700M)

Founding Partner – Softbank Capital (\$500M)

Venture Partner – VantagePoint Capital Partners (USD\$3B)

Co-Founder - EBT Mobile 数码通信 (China) LTD



BOARD OF DIRECTORS



Chairman Niall Cairns

BEc, ACA, FAICD

Managing Partner - Kestrel Capital Pty Limited

Director - Tru-Test Corporation Limited

Chairman - ComOps Limited (ASX: COM)

Director - Chant West Holdings Limited (ASX: CWL)

Managing Partner - Kestrel Growth Funds

Managing Partner - Carnethy Evergreen Fund



Executive Director & CEO
Craig R. Cooper
BEC, LLB (Hons)



Non-Executive Director R. King Nelson

BA, MBA

Director - Regenesis Biomedical

President, CEO & Director - Uptake Medical

Director - Digirad

President, CEO & Director - Kerberos Proximal Solutions

President, CEO & Director - VenPro Medical (Medtronic)

Division President - Baxter Healthcare (various businesses)

Sales & Marketing - American Hospital Supply

KEY MANAGEMENT



Doug Kurschinski

EVP & Head of Global Sales

Cardiac Pathways (Boston Scientific)

St Jude Medical (Abbott)

Stereotaxis



Jarrod White
Chief Financial Officer
Traverse Accountants
University of Sydney



ZiHan Lin

VP of Corporate Development

Masimo
Uptake Medical
Harvard / Stanford



Rhonda Welch

Strategic Market Access

J&J - Biosense Webster



Yervant Chijian

Director of RA & QA

ResMed

UT Sydney - Engineering



Lawrence Chan

Director of Product Development

Cochlear
Silverbrook Research




Harry Kim
Senior Advisor


Baxter Healthcare

American Well
Samsung Electronics
Hewlett Packard
Deloitte Consulting

CORPORATE HISTORY



Cardie



BUSINESS OVERVIEW

We provide digital and device based solutions for large scale population health disorders with significant market scale.


- Current focus is on cardiovascular disease (CVD) and heart health - the #1 cause of premature death globally.
- Our long term future lies in developing large scale health technologies in other significant global wellness markets (e.g. obesity, orthopedic health, diabetes management, urology).

Our health solutions and IP have the potential to disrupt multiple multi-billion dollar markets in preventative diagnostics, patient management, wearables, and consumer/digital health.





We provide investment exposure to 3 of the fastest growing global healthcare market opportunities.



OUR PORTFOLIO OF SOLUTIONS

Ecosystem of Synergistic Healthcare Technologies









Gold Standard Medical Technology

- Central blood pressure measurement technology for medical and research professionals.
- Turnkey clinical trial services.
- Strong IP portfolio for licensing with flexible integration options.
- Distribution partnerships in emerging markets throughout Asia-Pacific, China and Europe.

AI-Powered Wearable Sensors

- Ongoing cross-licensing partnership with technology undergoing clinical trials.
- Targeting "reference design" sales to wearable and consumer device makers (e.g. Apple, Garmin, etc.).
- Targeting direct product sales of CardieX health wearables.
- Co-development revenues from jointly developed Blumio+CardieX products and IP.

Consumer-Focused Digital Health

- Health coaching fees via Telemedicine platforms (e.g. Anthem, American Well, etc.).
- Sale of nutritional and health coaching subscriptions (devices, meal plans, supplements).
- Licensing inHealth program to wearable and consumer health companies (e.g. Xiaomi, Samsung, etc.).
- Mobile app sales.

New Product Development

- Commercial in confidence development of new products and services for USA and Chinese medical and consumer markets.
- Current focus on commercialization of CardieX IP in new devices and technologies.


OUR MISSION IS TO CREATE A SIGNIFICANT AND VALUABLE HEALTHCARE ECOSYSTEM OF COMPLIMENTARY PRODUCTS AND SERVICES




THE GLOBAL PROBLEM


A Worldwide Epidemic

CVD is the #1 killer of humans by non-natural causes





WE **MUST** FIND A BETTER WAY TO DETECT CVD AND MANAGE PATIENT HEALTH OUTCOMES.



All Cardiovascular Diseases (CVD)

10% Coronary Heart Disease

9% Stroke

5% Other Heart Diseases

2% Diseases of Arteries, Arterioles & Capillaries

1% Hypertensive Diseases

Other Diseases of the Circulatory System

STAGGERING FIGURES FROM CHINA

Hypertension Leads to Numerous Chronic Conditions

20M Stroke

290M CVD

120M CKD

245M HTN

435M pre-HTN 490M Pre-Diabetes

130M Diabetes

> 70M Obesity

60MSleep
Apnea

THE POWER OF CENTRAL PRESSURES

Advancing BP Management by Individualizing Drug Therapy

Conventional brachial blood pressure

is taken from here with a pressure cuff on the upper arm

Central pressure is from the ascending aorta,

and *this* is the pressure that causes stroke, heart attacks, and other central organ diseases.

But technology exists to accurately estimate central arterial pressure from features in the brachial pulse waveforms.

This has always meant to be an estimate of the **central pressure**, but much research over time has shown lack of accuracy for brachial pressure.

Central pressures have been thoroughly researched in the last two decades and shown to be more predictive of CHF, coronary heart disease, stroke, arteriosclerosis and kidney disease than brachial pressure, and they are also independently associated with diabetes and cognitive dysfunction.

ATCOR MEDICAL



Our Flagship Medical Technology for Hypertension Management

Significant Patent Portfolio and Clinically Proven Technology.

Our XCEL SphygmoCor® system allows specialist practitioners, pharmaceutical companies, as well as research institutions to non-invasively measure central arterial pressure in patients.

- Measuring central arterial pressure is the only way to accurately determine and predict pre-hypertension and arterial stiffness the main precursors to key organ damage and cardiovascular disease.
- The system detects key parameters associated with CVD that are usually only detected with an invasive catheter.
- The only FDA 501(k)-cleared and reimbursed device for sale in the USA deemed to be substantially equivalent to an invasive catheter for all central measurements.









EXISTING PARTNERS & CUSTOMERS

Recognized by Top Heathcare Providers and Pharmaceutical Companies



Countries



Installations

Pharmaceutical Companies




























Healthcare Providers







RECENT PUBLICATIONS FROM CHINA

Continued Publications in SCIE Journals from Tier 3A Chinese Institutions



Zuo JL, et al.
Central aortic pressure
improves prediction of
cardiovascular events
compared to peripheral
blood pressure in shortterm follow-up of a
hypertensive cohort.



Lu Y, et al.
Comparison of Carotid-Femoral and Brachial-Ankle Pulse-Wave
Velocity in Association
With Target Organ
Damage in the
Community-Dwelling
Elderly Chinese: The
Northern Shanghai
Study.



Yang L, et al.
Association of central
blood pressure and
cardiovascular diseases
in diabetic patients with
hypertension.



Hu M, et al.
Combined moderate and
high intensity exercise with
dietary restriction improves
cardiac autonomic function
associated with a
reduction in central and
systemic arterial stiffness
in obese adults: a clinical
trial.



Fu S, et al.

Multimarker Analysis for
New Biomarkers in
Relation to Central
Arterial Stiffness and
Hemodynamics in a
Chinese CommunityDwelling Population.











CURRENT ATCOR USERS IN CHINA

Trusted by Top Tier Medical Institutions Across the Country

































CHINA MARKET DEVELOPMENT

Continue Growth in Hospitals and Expand into Telemedicine and Consumer Health

Hospital Market

Strengthen clinical marketing of central BP and arterial stiffness across various specialties

Establish OEM partnerships with vital sign monitor manufacturers to integrate AtCor technology



Telemedicine Market

Focus on supplying clinically validated telehealth services and home health devices onto telemedicine platforms

Consumer Market

Focus consumer education efforts on the dangers of arterial stiffness

Establish technology partnerships with smart wearables maker and home BP monitor manufacturers to integrate AtCor technology


ATCOR MEDICAL APIS

Our Comprehensive Portfolio for OEMs across the Spectrum

Feature List	HEALTHX For smart wearables	HOMEX For BP monitors	MEDX For vital sign monitors
Heart Rate			
Augmentation Index			
Buckberg SEVR			
Reference Age			
Central BP - systolic/diastolic			
Central pulse pressure			
Pulse pressure amplification			
Mean Arterial Pressure			
Ejection Duration			
Reflection Magnitude			

ATCOR INSIDE - ATCOR EVERYWHERE

Flexible Integration to Maximize Adoption



INTEGRATION PROCESS



MEDX API

For Vital Sign Monitors

- For outpatient spot-check use
- Target care areas in hospital: Cardiology,
 Nephrology, Endocrinology, Hypertension Clinic
- Our most full-featured API with a comprehensive suite of proprietary central BP and arterial stiffness capabilities

INTEGRATION OPTIONS







Cloud-Based

Onboard Software

Embedded Chip

12:15:34 CardieX

FEATURES

- Augmentation Index
- Buckberg SEVR
- Reference Age
- Heart Rate
- Central SystolicPressure
- Central DiastolicPressure
- Central Pulse Pressure
- Pulse PressureAmplification
- Mean Arterial Pressure
- Ejection Duration
- Reflection Magnitude

HOMEX API

For Ambulatory & Home BP Monitors

- For non-hospital on-demand spot-check use
- Target devices: ambulatory BP monitors and home-use BP monitors
- Our mid-tier API featuring clinically useful and consumer-friendly central BP and arterial stiffness measurements

INTEGRATION OPTIONS







Cloud-Based

Onboard Software

Embedded Chip

2 1-2cm (1/2 inch) 3 SYS mmHg DIA PULSE /min

FEATURES

- Cardiac Load
- Exercise Capacity
- Vascular Age
- Heart Rate
- BPX Central SystolicPressure
- BPX Central DiastolicPressure
- CVD Risk Score

LEVERAGE THE POWER OF AI

Enriching the Largest Wearables Market on the Planet

623K 680M 43%

5 (D) M

Daily inpatient visits in China requiring BP monitoring

Hypertensive and pre-hypertensive in China

Urban Chinese consumers own wearable devices

Annual shipment of wearable devices in China

Financial & strategic

develop wearables that

can detect hypertension,

CVD and other health

disorders.

partnership to co-

Integrate Al analytics into smart wearable

3

Our Wearables Solution

devices.

Incorporate CardieX IP and trademarks into proprietary consumer applications for health and fitness.

HEALTHX API

For Smart Wearable Devices

- For daily use (continuous monitoring)
- Target wearables: smart bands, smartwatches, smart earbuds
- General health measurements related to arterial stiffness and cardiovascular function

INTEGRATION OPTIONS







Cloud-Based

Onboard Software

Embedded Chip



FEATURES

- Cardiac Load Vascular Age
- Exercise CapacityHeart Rate

PARTNERSHIP WITH BLUMIO

Co-Development of Next Generation Wearable Diagnostics

Strategic and financial partnership focused on developing wearable technologies for consumer-focused cardiovascular health based on the AtCor algorithm IP from CardieX/AtCor and advanced BP sensing IP from Blumio.

- Silicon Valley-based engineering and development team.
- Backed by Thiel Foundation (founded by Peter Thiel PayPal co-founder and first investor in Facebook).
- Developer of specialized radar frequency sensors for cardiovascular disease, hypertension, and health monitoring.
- First phase trial completed at Macquarie University, and larger scale trial at Deborah Heart and Lung Center (USA) commenced in November 2018.
- Deborah continues to successfully collect reference blood pressure data from subjects. Trial will continue until we have extracted enough relevant data to allow us to refine our algorithms - which is the ultimate goal of the study.
- Targeting ambulatory blood pressure monitoring opportunity - USD\$8B annual global market.



NEW ADDITION: INHEALTH



Comprehensive Portfolio of Clinically Validated Telehealth Services

Majority Acquisition of Leading Virtual Health Coaching and Telehealth Services Provider in USA.

- Providing digital, e-commerce and mobile tools for patients to connect online with health coaches as part of a patient care management program.
- Offering coaching programs based on multi-year published studies showing clinically significant health outcomes through use of inHealth's proprietary health coaching tools.
- Serving a USD\$25B industry in the USA growing at a compound rate of 18% per annum.
- Executing significant contracts with Anthem (NYSE:ANTM, USD\$70B), the second largest health insurance company in the USA, and American Well, the largest Telemedicine provider in the USA.
- Adding significant value to the CardieX healthcare and technology ecosystem.
- Financially accretive and positive to CardieX group in a short timeframe.

Provides "direct to consumer" and "direct to practitioner" channels for CardieX products and services as well as new healthcare initiatives (wearables, medical devices and digital health).



HEALTH COACHING IS THE MISSING LINK IN THE HEALTHCARE CHAIN

Any Device that "Mines" Patient-Generated Health Data Requires a Telehealth Solution



Mealth

"Hey Siri, how

can I lose

weight?"

Telehealth Coaching

inHealth provides the crucial link between data + diagnostics and better patient outcomes.

Connected Devices

Google Home

"Alexa, how can I reduce my blood sugar?"

Amazon Alexa Apple HomePod

INHEALTH CUSTOMIZED PROGRAMS

Designed to Drive Provider Revenue and Help Patients Meet Health Goals

Weight Loss Management

Nine different multidisciplinary Weight Loss programs focusing on Nutrition, Behavior and Fitness - all supported by inHealth-certified coaches.



Diabetes Prevention

inHealth-certified diabetes prevention dietitians and programs that comply with CDC's DPRP standards.



Sports Nutrition

inHealth-certified protocols for maximum performance and diet analysis services that include complete sports analysis.



LAUNCHING 2019

Hypertension Management

Evidence-based protocols combined with inHealth-certified coaches help users stay accountable and bring about significant blood pressure reductions safely.



LAUNCHING 2019

Sleep Health

Lifestyle intervention with weight management support from inHealth-certified coaches to improve sleep quality - from sleep hygiene to obstructive sleep apnea.



LAUNCHING 2019

Mental Health

inHealth-certified clinicians help patients address psychological factors that can be tied to chronic diseases, such as depression or anxiety.






For Medicare beneficiaries who have multiple chronic conditions like those listed above. Combine our programs!



INHEALTH CUSTOMIZED PROGRAMS

Designed to Drive Provider Revenue and Help Patients Meet Health Goals



CURRENT INHEALTH PIPELINE

Diverse Array of Corporate Telehealth Businesses*



Health Plans

> 50 Payers> 140M Covered Lives











Employers

> 2000 Employers



ORACLE®

jetBlue





Health Systems

70 Health Systems1000 Hospitals





 ${\color{red}Nemours}_{\text{\tiny{\$}}}$





Pharma

Integrated Support Beyond the Pill





Therapeutics MD[®]



Retails & Wellness


Extending Care to New Settings

SAMSUNG

PHILIPS




is not just about the volume of health data, it's about



CLINICAL ACTIONABLE EVIDENCE INSIGHTS

THE CARDIEX ECOSYSTEM



IN CHINA

Create local presence

FOR CHINA

Build local partnerships

BY CHINA

Leverage local manufacturing

THANK YOU

Craig Cooper

CEO

ccooper@cardiex.com
+61 0429 993 399

ZiHan Lin

VP of Corporate Development zlin@cardiex.com +1 818 800 1949

